The effect of rosuvastatin in a murine model of influenza a infection

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Radigan, Kathryn A ^a   Urich, Daniela ^a   Misharin, Alexander V ^a   Chiarella, Sergio E ^a   Soberanes, Saul ^a   Gonzalez, Angel ^a   Perlman, Harris ^a   Wunderink, Richard G ^a   Budinger, G R Scott ^a   Mutlu, Gökhan M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ROSUVASTATIN; ANTIVIRUS AGENT; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELL POPULATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; INFLUENZA A (H1N1); INFLUENZA VIRUS A; LUNG INJURY; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PNEUMONIA; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS REPLICATION; VIRUS STRAIN; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LUNG; MACROPHAGE; METABOLISM; ORTHOMYXOVIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; CYTOKINES; DISEASE MODELS, ANIMAL; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; LUNG; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMONIA; PYRIMIDINES; SULFONAMIDES; VIRUS REPLICATION;

EID: 84860010918     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035788     Document Type: Article

References (47)

1. Hamilton BE, Minino AM, Martin JA, Kochanek KD, Strobino DM, et al. (2007) Annual summary of vital statistics: 2005. Pediatrics 119: 345-360.
2. Johnson NP, Mueller J, (2002) Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 76: 105-115.
3. Shrestha SS, Swerdlow DL, Borse RH, Prabhu VS, Finelli L, et al. (2011) Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis 52 (Suppl 1): S75-82.
4. Fedson DS, Dunnill P, (2007) New approaches to confronting an imminent influenza pandemic. Perm J 11: 63-69.
5. Hayden FG, Pavia AT, (2006) Antiviral management of seasonal and pandemic influenza. J Infect Dis 194 (Suppl 2): S119-126.
6. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, et al. (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364: 759-765.
7. Centers for Disease Control and Prevention (CDC) (2009) Update: influenza activity- United States, September 28, 2008-January 31, 2009. MMWR Morb Mortal Wkly Rep 58: 115-119.
8. Hurt AC, Lee RT, Leang SK, Cui L, Deng YM, et al. (2011) Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 16.
9. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J, (2003) Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 63: 12-23.
10. Liao JK, (2002) Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110: 285-288.
11. Mortensen EM, Restrepo MI, Copeland LA, Pugh JA, Anzueto A, et al. (2007) Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy 27: 1619-1626.
12. Martin CP, Talbert RL, Burgess DS, Peters JI, (2007) Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy 27: 20-26.
13. Almog Y, Novack V, Eisinger M, Porath A, Novack L, et al. (2007) The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Critical Care Medicine 35: 372-378.
14. Almog Y, Shefer A, Novack V, Maimon N, Barski L, et al. (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110: 880-885.
15. Hackam DG, Mamdani M, Li P, Redelmeier DA, (2006) Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 367: 413-418.
16. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, et al. (2008) Preadmission use of statins and outcomes after hospitalization with pneumonia: A population-based cohort study of 29,900 adult patients. Pharmacoepidemiology and Drug Safety 17: S234-S235.
17. Mortensen EM, Pugh MJ, Copeland LA, Restrepo MI, Cornell JE, et al. (2008) Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. European Respiratory Journal 31: 611-617.
18. Chalmers JD, Singanayagam A, Murray MP, Hill AT, (2008) Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 121: 1002-1007 e1001.
19. Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR, (2007) Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 27: 325-332.
20. van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, et al. (2006) Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 61: 957-961.
21. Jing X, Ma C, Ohigashi Y, Oliveira FA, Jardetzky TS, et al. (2008) Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc Natl Acad Sci U S A 105: 10967-10972.
22. Matrosovich M, Matrosovich T, Garten W, Klenk HD, (2006) New low-viscosity overlay medium for viral plaque assays. Virol J 3: 63.
23. Schafer K, Kaiser K, Konstantinides S, (2005) Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. Thromb Haemost 93: 145-152.
24. Guo H, Shi Y, Liu L, Sun A, Xu F, et al. (2009) Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice. Arch Med Res 40: 345-351.
25. Desjardins F, Sekkali B, Verreth W, Pelat M, De Keyzer D, et al. (2008) Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. Eur Heart J 29: 128-137.
26. Mutlu GM, Green D, Bellmeyer A, Baker CM, Burgess Z, et al. (2007) Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway. J Clin Invest 117: 2952-2961.
27. Gupta R, Plantinga LC, Fink NE, Melamed ML, Coresh J, et al. (2007) Statin use and hospitalization for sepsis in patients with chronic kidney disease. Jama-Journal of the American Medical Association 297: 1455-1464.
28. Kwak B, Mulhaupt F, Myit S, Mach F, (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399-1402.
29. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, et al. (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7: 687-692.
30. Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, et al. (2009) Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 10: 45.
31. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, et al. (2001) An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103: 276-283.
32. Schonbeck U, Libby P, (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109: II18-26.
33. Kaiser L, Fritz RS, Straus SE, Gubareva L, Hayden FG, (2001) Symptom pathogenesis during acute influenza: Interleukin-6 and other cytokine responses. Journal of Medical Virology 64: 262-268.
34. Node K, Fujita M, Kitakaze M, Hori M, Liao JK, (2003) Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108: 839-843.
35. Makris D, Manoulakas E, Komnos A, Papakrivou E, Tzovaras N, et al. (2011) Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: Open-label, randomized study. Crit Care Med 39: 2440-2446.
36. Madjid M, Aboshady I, Awan I, Litovsky S, Casscells SW, (2004) Influenza and cardiovascular disease: is there a causal relationship? Tex Heart Inst J 31: 4-13.
37. Lippi G, Franchini M, Favaloro EJ, (2010) Influenza and cardiovascular disease: does swine-origin, 2009 H1N1 flu virus represent a risk factor, an acute trigger, or both? Semin Thromb Hemost 36: 49-58.
38. Puig-Barbera J, Diez-Domingo J, Varea AB, Chavarri GS, Rodrigo JA, et al. (2007) Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 25: 7313-7321.
39. Pastey MK, Gower TL, Spearman PW, Crowe JE Jr, Graham BS, (2000) A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nat Med 6: 35-40.
40. Catron DM, Lange Y, Borensztajn J, Sylvester MD, Jones BD, et al. (2004) Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation. Infect Immun 72: 1036-1042.
41. del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, et al. (2004) Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 200: 541-547.
42. Giguere JF, Tremblay MJ, (2004) Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 78: 12062-12065.
43. Macreadie IG, Johnson G, Schlosser T, Macreadie PI, (2006) Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett 262: 9-13.
44. Beutler B, Cerami A, (1987) Cachectin: more than a tumor necrosis factor. N Engl J Med 316: 379-385.
45. Yeh SS, Blackwood K, Schuster MW, (2008) The cytokine basis of cachexia and its treatment: are they ready for prime time? J Am Med Dir Assoc 9: 219-236.
46. Zarogiannis SG, Noah JW, Jurkuvenaite A, Steele C, Matalon S, et al. (2012) Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1). Life Sci.
47. Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, et al. (2008) A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 9: 1074-1083.